Hedge Fund and Insider Trading News: Bill Ackman, Cathie Wood, Crispin Odey, Elliott Management, Millennium Management, Modulo Capital, Maniyar Capital Advisors, Pyxis Oncology, Inc. (PYXS), Merrimack Pharmaceuticals Inc (MACK), and More
The U.S.
Merrimack Pharmaceuticals Inc (MACK)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Newtyn Management Noah Levy And Eugene Dozortsev | 1,873,694 | $23,027,699 | +6% | 4.52% |
| 2. | Madison Avenue Partners Eli Samaha | 553,085 | $6,797,415 | 1.46% | |
| 3. | 325,300 | $3,997,937 | +1% | 0% | |
| 4. | Sio Capital Michael Castor | 272,843 | $3,353,240 | +10% | 1.65% |
| 5. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 191,266 | $2,350,659 | -9% | 0.18% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.52 | 33,181 | 357,514 | 2023-03-21 | Filing | ||
| $11.52 | 127,409 | 1,412,044 | 2023-03-21 | Filing | ||
| $11.40 | 450 | Director, Other | 324,333 | 2023-01-31 | Filing | |
| $11.40 | 1,782 | Director, Other | 1,284,635 | 2023-01-31 | Filing | |
| $11.36 | 4,985 | Director, Other | 323,883 | 2023-01-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.84 | 1,000 | Director | 0 | 2021-12-31 | Filing | |
| $6.39 | 52,914 | Director, Other | 269,338 | 2021-07-01 | Filing | |
| $3.20 | 6,228 | Officer, Director | 0 | 2020-07-22 | Filing | |
| $3.20 | 17,250 | Officer, Director | 0 | 2020-07-22 | Filing | |
| $3.04 | 52,068 | Officer, Director | 0 | 2020-07-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 1,672,463 | $20,554,570 | 20.85% | |
| 2. | 466,140 | $5,728,861 | 0% | |
| 3. | 458,521 | $5,635,223 | 0% | |
| 4. | 294,545 | $3,619,958 | 0.33% | |
| 5. | 222,253 | $2,731,490 | 0% |
News See All
12 Best Performing Biotech Stocks in 2022
Fitch Ratings has assigned a Neutral rating to the global pharmaceutical and biotech industry, which indicates the assumption of a collaborative operating backdrop in 2023, although inflationary pressures...
Hedge Fund and Insider Trading News: Kyle Bass, Daniel Och, Bill Ackman, Perceptive Advisors, Schonfeld Strategic Advisors, Coatue Management, Merrimack Pharmaceuticals Inc (MACK), AMC Entertainment Holdings Inc (AMC), and More
Closely watched hedge fund manager Kyle Bass said Thursday that oil prices could rise "well north of $100" in 2022 as a lack of investment in the hydrocarbon industry meets a surge in demand as the global...
Hedge Fund and Insider Trading News: Steve Cohen, Bill Ackman, Nicolai Tangen, Dan Loeb, Legion Partners Asset Management, Tyr Capital Partners, Archegos Capital Management, Artis Real Estate Investment Trust Unit (ARESF), Moderna Inc (MRNA), and More
BOSTON (Reuters) - Activist investor Legion Partners Asset Management LLC has nominated seven directors to sit on specialty retailer Genesco Inc’s eight-person board, according to a letter made public...
Where Do Hedge Funds Stand On Merrimack Pharmaceuticals Inc (MACK)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...
Hedge Fund and Insider Trading News: Ray Dalio, Warren Buffett, Fortress Investment Group, Fulcrum Asset Management, Guess?, Inc. (GES), Merrimack Pharmaceuticals Inc (MACK), and More
A ransomware attack against a vendor of SEI Investments Co.
Hedge Funds Are Selling Merrimack Pharmaceuticals Inc (MACK)
Is Merrimack Pharmaceuticals Inc (NASDAQ:MACK) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research...
13D Filing: JFL Capital Management and Merrimack Pharmaceuticals Inc (NASDAQ:MACK)
Joseph F. Lawler's JFL Capital disclosed a 7.1% activist stake in Merrimack Pharmaceuticals.
Merrimack Pharmaceuticals Inc (MACK) Cancer Drugs Sold To Ipsen
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has resolved to dispose of its cancer drugs unit to Ipsen. Some of these drugs include Doxil and Onivyde.
Is Merrimack Pharmaceuticals Inc (MACK) A Good Stock To Buy?
Looking for high-potential stocks? Just follow the big players within the hedge fund industry.
Billionaire Hedge Funds
